Scanfil plc Stock exchange release 25 October 2024 at 2.30 p.m EEST
Decision of Scanfil plc’s Board of Directors on distributing 2022CI and 2022CII stock option rights
Today, on 25 October 2024 Scanfil plc’s Board of Directors has decided to distribute stock option rights to key personnel of Scanfil Group.
The CEO, the members of the Management Team and other 21 key personnel were distributed in total 370,000 option rights of which the CEO Christophe Sut 120,000 pcs, and the members of the Management Team 20,000 pcs each and other key personnel 130,000 pcs in total. Distributed option rights are marked as “2022CI” and “2022CII”.
Each option right entitles its holder to subscribe for one (1) new or existing share held by the company. The subscription period for option rights 2022CI and 2022CII is 1 May 2027 – 30 April 2029. The subscription period for the option rights included in the option plan will not begin unless the production and financial goals and conditions, set separately by the Board of Directors for exercising the option rights, are met.
The option rights for which the goals are not met will expire as determined by the Board of Directors. The stock options were distributed gratuitously. The subscription price of option rights 2022CI and 2022CII is the trade volume weighted average price of the Scanfil plc share on Nasdaq Helsinki Ltd during the period of 1 November – 30 November 2024.
Distribution of option rights is based on the authorization given on 21 April 2022 by the Annual General Meeting of Shareholders to the Board of Directors to decide on an issue of stock options. The Board of Directors decided on the option plan and the issuance of a maximum total of 1,200,000 stock options on 27 October 2022.
The terms and conditions of the option plan can be found here: https://www.scanfil.com/investors/annual-general-meetings/option-scheme
Scanfil plc
Board of Directors
Additional information:
Chairman of the Board of Directors, Harri Takanen
tel. +358 8 4882 111
Scanfil in brief
Scanfil plc is Europe’s largest listed provider of electronics manufacturing services (EMS), whose turnover in 2023 amounted to EUR 902 million. The company serves global sector leaders in the customer segments of Industrial, Energy & Cleantech, and Medtech & Life Science. The company’s services include design services, prototype manufacture, design for manufacturability (DFM) services, test development, supply chain and logistics services, circuit board assembly, manufacture of subsystems and components, and complex systems integration services. Scanfil’s objective is to grow customer value by improving their competitiveness and by being their primary supply chain partner and long-term manufacturing partner internationally. Scanfil’s longest-standing customer account has continued for more than 30 years. The company has global supply capabilities and nine production facilities across three continents. www.scanfil.com